# Chengdu New Radiomedicine Technology

Source: https://onco.cc/companies/chengdu-new-radiomedicine-technology/  
OnCo record `chengdu-new-radiomedicine-technology` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Chengdu New Radiomedicine Technology is a Chinese company that makes medical radioisotopes and radioactive cancer medicines. It is testing a FAP-targeted scan agent and treatment in advanced solid tumours, and a radioactive treatment given with chemotherapy in pancreatic cancer.

## Summary

Chengdu New Radiomedicine Technology Co., Ltd. (成都纽瑞特医疗科技股份有限公司, NRT Medtech) was founded in 2016 in Shuangliu, Chengdu, according to the company, and works across the radiopharmaceutical chain: medical isotope production (including yttrium-90, lutetium-177 and actinium-225, and a germanium-68/gallium-68 generator), radioactive microsphere drugs built on its own carbon microsphere carrier, and radioligand therapy. Its marketed products include yttrium-90 carbon microsphere injection. The NRT6020 programme targets fibroblast activation protein (FAP) and pairs gallium-68 for PET imaging with lutetium-177 and yttrium-90 for therapy; China's CDE cleared 90Y-NRT6020 for clinical study in October 2026. The company has subsidiaries in Australia and the United States and began IPO tutoring in 2025. Its first registered cancer trial, NCT06278454, a phase 1 dose-escalation and expansion study of NRT6008 injection with gemcitabine-nab-paclitaxel or FOLFIRINOX chemotherapy in unresectable locally advanced or node-positive advanced pancreatic cancer, was posted on ClinicalTrials.gov in February 2024. NCT06911489, a phase 1 study of 68Ga-NRT6020 and 177Lu-NRT6020 in FAP-positive advanced solid tumours, was posted in April 2025.

## Fields

- Kind: Company
- Last checked: 2026-10-29
- Also known as: Chengdu New Radiomedicine Technology Co., Ltd.; NRT Medtech; 成都纽瑞特医疗科技股份有限公司
- HQ: Chengdu
- Type: radiopharma
- Website: http://www.nrtmedtech.com/

## Notes

- The composition of NRT6008 is not stated in the registry record or on the pages read; it is not linked to the carbon microsphere product here.
- Financing rounds and amounts are not stated on the company website.
- Company website (Chinese) read on 29 October 2026.

## Sources

- Official website: http://www.nrtmedtech.com/
- Company news: 90Y-NRT6020 cleared for clinical study, October 2026 (Chinese): http://www.nrtmedtech.com/xinwendongtai/184.html
- ClinicalTrials.gov: phase 1 trial of NRT6008 with chemotherapy in pancreatic cancer (NCT06278454): https://clinicaltrials.gov/study/NCT06278454
- ClinicalTrials.gov: phase 1 trial of 68Ga- and 177Lu-NRT6020 in FAP-positive solid tumours (NCT06911489): https://clinicaltrials.gov/study/NCT06911489

## Connected records

- cancers: [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)
- fronts: [Radiopharmaceuticals & Theranostics](https://onco.cc/fronts/radiopharma/)
- technologies: [FAPI PET](https://onco.cc/technologies/fapi-pet/), [Radioligand therapy (beta emitters)](https://onco.cc/technologies/radioligand-therapy/)
- targets: [FAP](https://onco.cc/targets/fap/)

---
JSON: https://onco.cc/api/v1/entities/chengdu-new-radiomedicine-technology.json